Advertisement

Supportive Care in Cancer

, Volume 18, Issue 3, pp 273–279 | Cite as

Evolving classification systems for cancer cachexia: ready for clinical practice?

  • David Blum
  • Aurelius Omlin
  • Ken Fearon
  • Vickie Baracos
  • Lukas Radbruch
  • Stein Kaasa
  • Florian StrasserEmail author
  • European Palliative Care Research Collaborative
Review Article

Abstract

Introduction

Involuntary weight loss, the defining factor of cachexia, is a common consequence of advanced cancer.

Discussion

This review summarizes the actual cachexia definitions and classification systems (NCCTG-studies, Loprinzi et al.; PG-SGA, Ottery et al.; Cachexia Consensus Conference, Evans et al; Cancer Cachexia Study Group, Fearon et al.; and SCRINIO Working group, Bozzetti et al.). We describe the ongoing development of a new classification system for cancer cachexia, which is based on literature reviews and Delphi processes within the European Palliative Care Research Collaborative. The review describes the evolving understanding of the pathophysiological mechanisms of cachexia and outlines an overview on treatment options.

Conclusion

In this review an outlook on the requirements of a new decision guiding instrument is given and the challenges in clinical decision making in palliative are discussed.

Keywords

Cancer Classification systems Cancer cachexia 

References

  1. 1.
    Bozzetti F, on behalf of the SCRINIO Working Group (2009) Screening the nutritional status in oncology: a preliminary report on 1, 000 outpatients. Support Care Cancer 17(3):279–284CrossRefPubMedGoogle Scholar
  2. 2.
    Hopkinson JB, Wright DN, McDonald JW, Corner JL (2006) The prevalence of concern about weight loss and change in eating habits in people with advanced cancer. J Pain Symptom Manage 32:322–331CrossRefPubMedGoogle Scholar
  3. 3.
    Davis MP, Dickerson D (2000) Cachexia and anorexia: cancer’s covert killer. Support Care Cancer 8:180–187CrossRefPubMedGoogle Scholar
  4. 4.
    Loprinzi CL (1995) Management of cancer anorexia/cachexia. Support Care Cancer 3:120–122CrossRefPubMedGoogle Scholar
  5. 5.
  6. 6.
    Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Mailliard JA, Bushey TI, Nair S, Christensen B, North Central Cancer Treatment Group (2004) An eicosapentaenoic acid supplement versus megestrol acetateversus both for patients with cancer-associated wasting: a North Central CancerTreatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 22(12):2469–2476CrossRefPubMedGoogle Scholar
  7. 7.
    Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20(2):567–573CrossRefPubMedGoogle Scholar
  8. 8.
    Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD (2008) Cachexia: a new definition. Clin Nutr 27(6):793–799CrossRefPubMedGoogle Scholar
  9. 9.
    Bozzetti F, Mariani L (2009) Defining and classifying cancer cachexia: a proposal by the SCRINIO working group. JPEN J Parenter Enteral Nutr 33(4):361–367CrossRefPubMedGoogle Scholar
  10. 10.
    Stone P, Richards M, A’Hern R, Hardy J (2000) A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 11(5):561–567CrossRefPubMedGoogle Scholar
  11. 11.
    Strasser F (2008) Diagnostic criteria of cachexia and their assessment: decreased muscle strength and fatigue. Curr Opin Clin Nutr Metab Care 11(4):417–421CrossRefPubMedGoogle Scholar
  12. 12.
    Birgegård G, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, Krzakowski M, Ludwig H, Pecorelli S, Schmoll H, Schneider M, Schrijvers D, Shasha D, Van Belle S (2005) Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 68(Suppl 1):3–11CrossRefPubMedGoogle Scholar
  13. 13.
    Knudsen A, Aass N, Fainsinger R, Caraceni A, Klepstad P, Jordhøy M, Hjermstad M, Kaasa S (2009) Classification of pain in cancer patients—a systematic literature review. Palliat Med 23:295–308CrossRefPubMedGoogle Scholar
  14. 14.
    Rayner L, Loge JH, Wasteson E, Higginson IJ (2009) EPCRC, European Palliative Care Research Collaborative. The detection of depression in palliative care. Curr Opin Support Palliat Care 3:55–60CrossRefPubMedGoogle Scholar
  15. 15.
    Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D et al (2008) Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 26:3702–3708CrossRefPubMedGoogle Scholar
  16. 16.
    Takahashi Y, Yasumoto K, Mai M (2005) Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy. Oncol Rep 14:135–140PubMedGoogle Scholar
  17. 17.
    Ravasco P, Monteiro Grillo I, Camilo M (2007) Cancer wasting and quality of life react to early individualized nutritional counselling! Clin Nutr 26:7–15CrossRefPubMedGoogle Scholar
  18. 18.
  19. 19.
    Baracos VE (2006) Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr 26:13.1–13.27CrossRefGoogle Scholar
  20. 20.
    Tisdale MJ (2008) Catabolic mediators of cancer cachexia. Curr Opin Support Palliat Care 2(4):256–261CrossRefPubMedGoogle Scholar
  21. 21.
    Yavuzsen T, Mellar PD, Walsh D et al (2005) Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 85:8500–8511CrossRefGoogle Scholar
  22. 22.
    Fearon KC, Barber MD, Moses AG et al (2006) Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24:3401–3407CrossRefPubMedGoogle Scholar
  23. 23.
    Strasser F, Luftner D, Possinger K et al (2006) Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-relatedanorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24:3394–3400CrossRefPubMedGoogle Scholar
  24. 24.
    Sarhill N, Mahmoud F, Walsh D, Nelson KA, Komurcu S, Davis M, LeGrand S, Abdullah O, Rybicki L (2003) Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer 11(10):652–659CrossRefPubMedGoogle Scholar
  25. 25.
    Chang VT, Xia Q, Kasimis B (2005) The Functional Assessment of Anorexia/Cachexia Therapy (FAACT) appetite scale in veteran cancer patients. J Support Oncol 3:377–382PubMedGoogle Scholar
  26. 26.
    Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG (2005) Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care—correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 103(10):2189–2198CrossRefPubMedGoogle Scholar
  27. 27.
    Fearon KC, Voss AC, Hustead DS (2006) Cancer Cachexia Study Group. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83(6):1345–1350PubMedGoogle Scholar
  28. 28.
    Bosaeus I, Daneryd P, Svanberg E, Lundholm K (2001) Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer 93(3):380–383CrossRefPubMedGoogle Scholar
  29. 29.
    Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1, 000 patients. Support Care Cancer 8(3):175–179CrossRefPubMedGoogle Scholar
  30. 30.
    Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 34(1):94–104CrossRefPubMedGoogle Scholar
  31. 31.
    Tishelman C, Petersson LM, Degner LF, Sprangers MA (2007) Symptom prevalence, intensity, and distress in patients with inoperable lung cancer in relation to time of death. J Clin Oncol 25(34):5381–5389CrossRefPubMedGoogle Scholar
  32. 32.
    Pisters PW, Cersosimo E, Rogatko A, Brennan MF (1992) Insulin action on glucose and branched-chain amino acid metabolism in cancer cachexia: differential effects of insulin. Surgery 111(3):301–310PubMedGoogle Scholar
  33. 33.
    Del Fabbro E, Dalal S, Delgado M, Freer G, Bruera E (2007) Secondary vs primary cachexia in patients with advanced cancer. J Clin Oncol 25:9128Google Scholar
  34. 34.
    Hutton JL, Baracos VE, Wismer WV (2007) Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manage 33:156–165CrossRefPubMedGoogle Scholar
  35. 35.
    Bernhardson BM, Tishelman C, Rutqvist LE (2008) Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 16(3):275–283CrossRefPubMedGoogle Scholar
  36. 36.
    Rubenstein EB, Peterson DE, Schubert M et al (2004) Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046CrossRefPubMedGoogle Scholar
  37. 37.
    Sonis ST, Fey EG (2002) Oral complications of cancer therapy. Oncology (Williston Park) 16:680–686Google Scholar
  38. 38.
    Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, Willey J, Strasser F, Palmer JL (2004) Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage 28(4):381–388CrossRefPubMedGoogle Scholar
  39. 39.
    Strasser F (2003) Management of specific symptoms and syndromes: constipation. In: Bruera E, Fisch M (eds) Cambridge Handbook of Advanced Cancer Care Chapter 49. Cambridge University Press, Cambridge, pp 397–497Google Scholar
  40. 40.
    Qian L, Orr WC, Chen JD (2002) Inhibitory reflexive effect of rectal distension on postprandial gastric myoelectrical activity. Dig Dis Sci 47(11):2473–2479CrossRefPubMedGoogle Scholar
  41. 41.
    Mercadante S, Villari P, Ferrera P, Casuccio A (2006) Opioid-induced or pain relief-reduced symptoms in advanced cancer patients? Eur J Pain 10(2):153–159CrossRefPubMedGoogle Scholar
  42. 42.
    Chiu TY, Hu WY, Lue BH, Yao CA, Chen CY, Wakai S (2004) Dyspnea and its correlates in taiwanese patients with terminal cancer. J Pain Symptom Manage 28(2):123–132CrossRefPubMedGoogle Scholar
  43. 43.
    Grosvenor M, Bulcavage L, Chlebowski RT (1989) Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy dministration. Cancer 63(2):330–334CrossRefPubMedGoogle Scholar
  44. 44.
    Strasser F, Bruera E (eds) (2002) Cancer anorexia/cachexia syndrome: epidemiology, pathogenesis, and assessment. In gastrointestinal symptoms in advanced cancer patients. Oxford University Press, OxfordGoogle Scholar
  45. 45.
    Strasser F, Binswanger J, Cerny T et al (2007) Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study. Palliat Med 21:129–137CrossRefPubMedGoogle Scholar
  46. 46.
    Shragge JE, Wismer WV, Olson KL, Baracos VE (2007) Shifting to conscious control: psychosocial and dietary management of anorexia by patients with advanced cancer. Palliat Med 21:227–233CrossRefPubMedGoogle Scholar
  47. 47.
    Giordano KF, Jatoi A (2005) The cancer anorexia/weight loss syndrome: therapeutic challenges. Curr Oncol Rep 7:271–276CrossRefPubMedGoogle Scholar
  48. 48.
    Hoda D, Jatoi A, Burnes J, Loprinzi C, Kelly D (2005) Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A single institution’s 20-year experience. Cancer 103(4):863–868CrossRefPubMedGoogle Scholar
  49. 49.
    Bruera E, Belzile M, Neumann C et al (2000) A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage 19(6):427–435CrossRefPubMedGoogle Scholar
  50. 50.
    Berenstein EG, Ortiz Z (2005) Megestrol acetate for the treatment ofanorexia-cachexia syndrome. Cochrane Database Syst Rev 2:CD004310PubMedGoogle Scholar
  51. 51.
    Read JA, Beale PJ, Volker DH, Smith N, Childs A, Clarke SJ (2007) Nutrition intervention using an eicosapentaenoic acid-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Support Care Cancer 15:301–307CrossRefPubMedGoogle Scholar
  52. 52.
    Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ et al (2006) Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24:3401–3407CrossRefPubMedGoogle Scholar
  53. 53.
    Dewey A, Baughan C, Dean T, Higgins B, Johnson I (2007) Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 1:CD004597PubMedGoogle Scholar
  54. 54.
    Inoue A, Yamada Y, Matsumura Y et al (2003) Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer 11:528–532CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • David Blum
    • 1
  • Aurelius Omlin
    • 1
  • Ken Fearon
    • 2
  • Vickie Baracos
    • 3
  • Lukas Radbruch
    • 4
  • Stein Kaasa
    • 5
  • Florian Strasser
    • 1
    Email author
  • European Palliative Care Research Collaborative
  1. 1.Oncological Palliative Medicine, Division of Oncology/Hematology, Department of Internal Medicine and Palliative Care CenterCantonal HospitalSt. GallenSwitzerland
  2. 2.Clinical and Surgical Sciences, School of Clinical Sciences and Community Health, Royal InfirmaryThe University of EdinburghEdinburghUK
  3. 3.Department of OncologyUniversity of AlbertaEdmontonCanada
  4. 4.Department of Palliative MedicineRWTH Aachen UniversityAachenGermany
  5. 5.Faculty of MedicineClinical Department of Cancer Research and Molecular MedicineTrondheimNorway

Personalised recommendations